



The Corporate Strategic Intelligence you need!

Press Release

Grez-Doiceau, Belgium, October 2, 2012

**THE GLOBAL PROTON THERAPY MARKET WILL REACH US\$ 2.2 BILLION IN 2032, GROWING BY 9% ANNUALLY.**

CSIntell publishes the world's first Proton Therapy market report. Table of contents is available at: <http://www.csintell.com/market.html>

Today there are 39 proton therapy facilities for a total of 106 treatment rooms treating patients around the world, representing merely 0.8% of all conventional radiotherapy systems. By 2017 there will be 255 operational proton therapy treatment rooms.

Proton therapy remains a niche market however it is just coming up and growing fast. It has been subject to substantial interests in the past decade and it is expected that there will be a significant growth in proton treatment facilities around the world in the foreseeable future. The global proton therapy devices market is forecast to grow from US\$ 350 million in 2011 to US\$ 2.2 billion in 2032, showing an average annual growth of 9%. By 2032 there will be 1,000 proton therapy treatment rooms to treat patients on a regular basis. IBA clearly dominated the world market for the past 20 years. However since several years other vendors are increasing their market share. For the year 2017, it is estimated that IBA will hold just over 30% of the world particle therapy market, followed by Varian with 15% and Mitsubishi and Hitachi holding a little less than 10% market share each.

This proton therapy MarketR™ report features a comprehensive review of the market dynamics and analyzes both past and future trends to the year 2032. The report key benefits include: Market size and shares; Future trends and potential to 2032; Maps and list of all operational and future PT centers; Economics of proton therapy including reimbursement policies; Profile of PT competitors. It covers also carbon therapy.

The Proton Therapy Global MarketR™ report may prove valuable for industry insiders, finance professionals (analysts, investors), media, as well as potential new proton therapy centers, etc... The report has been prepared by Paul-Emmanuel GOETHALS, MBA.

For more information and to order your copy, please send an e-mail with your contact details to [paul@csintell.com](mailto:paul@csintell.com)

**About CSIntell**

CSIntell provides the Corporate Strategic Intelligence you need!

Paul-Emmanuel Goethals founded CSIntell as a new approach to connect Strategic Information needed by Top Executives to business needs, in a concise and understandable way.

Paul-Emmanuel has 23 years of experience in consulting, business development, intelligence and investors relations with a unique understanding of medical/healthcare markets.

Most recently he was Vice President Business Development & Capital Markets and Special Counsel to the CEO at Eckert & Ziegler Group and he was Director Corporate Business Development & Investor Relations at IBA for 11 years.

Please visit us at: [www.csintell.com](http://www.csintell.com)

**Contact**

**CSIntell**

**Paul-Emmanuel GOETHALS, MBA**

Founder, Management Consultant

Mobile: +32 491 080 968

e-mail: [paul@csintell.com](mailto:paul@csintell.com)